We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Beximco Pharma | LSE:BXP | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 39.00 | 38.00 | 40.00 | 39.00 | 39.00 | 39.00 | 10,000 | 08:00:00 |
TIDMBXP
RNS Number : 9344R
Beximco Pharmaceuticals Ltd
01 November 2023
1 November 2023
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS LIMITED.
Results for the year ended 30 June 2023
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the year ended 30 June 2023.
Financial Highlights (consolidated)
-- Net sales increased 13.3% to Bangladesh Taka ("BDT") 39,266.7m / GBP288.6m (2021-22: BDT 34,669.2m / GBP309.7m). The decline in revenue when translated to British Pounds reflects the significant local currency depreciation over the period
o Domestic sales increased 14.1% to BDT 36,503m/ GBP268.3m (2021-22: BDT 31,984.1m / GBP285. 8m)
o Export sales increased 2.9% to BDT 2,763.2m / GBP20.3m (2021-22: BDT 2,685.1m / GBP24.0m)
-- Profit after tax decreased 9.5% to BDT 4,524.5m / GBP33.3m (2021-22: BDT 4,998.6m / GBP44.7m)
-- EPS for the year amounted to BDT 10.34 (2021-22:BDT 11.48) -- Recommended 35% cash dividend (BDT 3.5 per share)
-- Absence of non-recurring vaccine distribution fee income in the reporting period and rising costs driven by significant depreciation of domestic currency and high inflation impacted profit despite growth in revenue
Operational Highlights - Continued focus on execution; enhanced portfolio for domestic and global export markets
-- Launched 14 new generics in 23 different presentations in Bangladesh, including Mulina (Lefamulin) an anti-infective drug for the first time
-- Completed 33 new registrations of 19 generics (23 Presentations) in 17 other countries worldwide
-- Received three product approvals from the US FDA
o Eletriptan (an antimigraine drug), Oxybutynin (an anticholinergic drug), and Nebivolol (a cardiovascular drug)
-- Obtained approvals from the Therapeutic Goods Administration in Australia for three products
o Bromhexine tablet (a mucolytic), Doxylamine Succinate tablet (an antihistamine), and Ibuprofen tablet (a non-steroidal anti-inflammatory drug)
-- Secured Health Canada approval for Ketorolac tablet, a drug used for pain management -- Earned the National Export Trophy (Gold) for a record seventh time
-- Won the Global Generics & Biosimilars (GGB) Awards 2022 in the category 'Acquisition of the Year'
Post Period Highlights
-- Launched 15 new generics (22 presentations) in the domestic market in the first quarter, of which 10 were for the first time in Bangladesh
-- Won National Export Trophy (Gold) for the eighth time
-- Nominated for the Global Generics & Biosimilars Awards 2023 as finalist in the category of "Company of the year, Asia Pacific."
Beximco Pharma Managing Director Nazmul Hassan MP commented:
"We have once again been able to deliver significant revenue growth for the financial year, which is a testament to the underlying strength of the business. Our continued focus on operational delivery meant that, over the period, we were able to launch a range of new products, attain notable regulatory approvals in key markets and continue to deliver high-quality, affordable medicines to patients around the world. However, macroeconomic factors resulting in double digit currency depreciation and inflationary pressures across our supply chain impacted our bottom line performance. As we begin the current financial year amidst these headwinds, we continually focus on strategies to address the challenges and deliver results for our shareholders."
Exchange rates of GBP1 = Taka 111.93 for 2021-22 numbers and GBP1 = Taka 136.05 for 2022-23 numbers have been used in this announcement.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 586/11001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position
As at June 30, 2023
Amount in Taka June 30, June 30, 2023 2022 ASSETS Non-Current Assets 48,280,929,007 47,728,777,460 Property, Plant and Equipment- Carrying Value 42,245,615,338 41,593,480,364 Right-of-use Assets 562,223,398 618,891,376 Intangible Assets 4,721,034,633 4,729,838,408 Deferred Tax Asset 56,512,081 88,640,228 Goodwill 674,570,185 674,570,185 Other Investments 20,973,372 23,356,899 Current Assets 20,875,854,240 18,419,258,282 Inventories 12,133,277,975 10,405,295,079 Spares & Supplies 819,740,355 718,797,256 Accounts Receivable 3,574,654,461 3,142,817,194 Loans, Advances and Deposits 2,984,876,883 2,787,039,904 Advance Income Tax 227,618,388 196,635,028 Cash and Cash Equivalents 1,135,686,178 1,168,673,821 -------------- ---------------- TOTAL ASSETS 69,156,783,247 66,148,035,742 -------------- ---------------- EQUITY AND LIABILITIES Equity Attributable to the Owners of the Company 43,680,703,738 40,600,497,817 Issued Share Capital 4,461,120,890 4,461,120,890 Share Premium 5,269,474,690 5,269,474,690 Excess of Issue Price over Face Value of GDRs 1,689,636,958 1,689,636,958 Capital Reserve on Merger 294,950,950 294,950,950 Revaluation Surplus 1,141,177,755 1,116,896,688 Unrealized Gain/(Loss) 18,148,196 20,531,723 Retained Earnings 30,806,194,299 27,747,885,918 Non-Controlling Interest 3,938,962,240 4,035,506,641 TOTAL EQUITY 47,619,665,978 44,636,004,458 Non-Current Liabilities 8,272,093,233 8,776,099,208 Long Term Borrowings-Net of Current Maturity 2,550,833,254 3,454,188,843 Liability for Gratuity, Pension and WPPF & Welfare Funds 3,170,764,435 2,785,072,661 Deferred Tax Liability 2,550,495,544 2,536,837,704 Current Liabilities and Provisions 13,265,024,036 12,735,932,076 Short Term Borrowings 6,621,170,271 6,850,550,319 Long Term Borrowings-Current Maturity 1,439,895,168 2,065,962,471 Creditors and Other Payables 3,531,707,176 2,478,930,393 Accrued Expenses 1,129,699,385 1,152,990,410 Dividend Payable / Unclaimed Dividend 88,465,109 88,049,428 Income Tax Payable 454,086,927 99,449,055 -------------- ---------------- TOTAL EQUITY AND LIABILITIES 69,156,783,247 66,148,035,742 -------------- ----------------
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the Year ended June 30, 2023
Amount in Taka July 2022- July 2021- June 2023 June 2022 Net Revenue 39,266,662,237 34,669,172,052 Cost of Goods Sold (21,953,290,466) (18,848,962,107) ---------------- ---------------- Gross Profit 17,313,371,771 15,820,209,945 ---------------- ---------------- Operating Expenses (10,097,131,808) (8,938,466,002) ---------------- ---------------- Administrative Expenses (1,180,124,415) (1,136,591,808) Selling, Marketing and Distribution Expenses (8,917,007,393) (7,801,874,194) ---------------- ---------------- Profit from Operations 7,216,239,963 6,881,743,943 Other Income 452,657,744 1,166,259,166 Finance Cost (1,285,698,253) (1,001,835,523) Profit Before Contribution to WPPF & Welfare Funds 6,383,199,454 7,046,167,586 Contribution to WPPF & Welfare Funds (314,430,512) (359,222,585) ---------------- ---------------- Profit Before Tax 6,068,768,942 6,686,945,001 Income Tax Expenses (1,544,300,452) (1,688,316,804) ---------------- ---------------- Current Tax (1,468,598,852) (1,191,180,488) Deferred Tax Income/ (Expense) (75,701,600) (497,136,316) ---------------- ---------------- Profit After Tax 4,524,468,490 4,998,628,197 Profit/(Loss) Attributable to: ---------------- ---------------- Owners of the Company 4,614,066,147 5,123,136,712 Non-Controlling Interest (89,597,657) (124,508,515) ---------------- ---------------- 4,524,468,490 4,998,628,197 Other Comprehensive Income/(Loss) (2,383,527) 6,764,517 ---------------- ---------------- Total Comprehensive Income 4,522,084,963 5,005,392,714 Total Comprehensive Income Attributable to: ---------------- ---------------- Owners of the Company 4,611,682,620 5,129,901,229 Non-Controlling Interest (89,597,657) (124,508,515) ---------------- ---------------- 4,522,084,963 5,005,392,714 ================ ================ Earnings Per Share (EPS) 10.34 11.48
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity
For the Year Ended June 30, 2023
As at June 30, 2023 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Share Share Excess Capital Revaluation Unrealized Retained Equity Non- Total Capital Premium of Issue Reserve Surplus Gain/ Earnings attributable Controlling Equity Price on Merger (Loss) to Owners Interests over of the Face Company Value of GDRs ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Balance as on July 01, 2022 4,461,120,890 5,269,474,690 1,689,636,958 294,950,950 1,116,896,688 20,531,723 27,747,885,918 40,600,497,817 4,035,506,641 44,636,004,458 ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Total Comprehensive Income: Profit for the Year - - - - - - 4,614,066,147 4,614,066,147 (89,597,657) 4,524,468,490 ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Other Comprehensive Income/(Loss) - - - - - (2,383,527) - (2,383,527) - (2,383,527) ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Transfer from deferred tax - - - - 28,647,841 - - 28,647,841 - 28,647,841 ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Transactions with the Shareholders: Cash Dividend - - - - - - (1,561,392,312) (1,561,392,312) (6,946,744) (1,568,339,056) ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Adjustment for Depreciation on Revalued Assets - - - - (5,634,546) - 5,634,546 - - - ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Adjustment for Deferred Tax on Revalued Assets - - - - 1,267,772 - - 1,267,772 - 1,267,772 ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Balance as on June 30, 2023 4,461,120,890 5,269,474,690 1,689,636,958 294,950,950 1,141,177,755 18,148,196 30,806,194,299 43,680,703,738 3,938,962,240 47,619,665,978 ------------- ------------- ------------- ------------- --------------- ----------- ------------------------ --------------- ------------- --------------- Number of Shares 446,112,089 Net Asset Value (NAV) Per Share Tk. 97.91 -------------------------------------------- --------------------- ------------- -------------------- ------------------------ --------------- ------------- --------------- As at June 30, 2022 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- Share Share Excess Capital Revaluation Unrealized Retained Equity Non- Total Capital Premium of Issue Reserve Surplus Gain/ Earnings attributable Controlling Equity Price on (Loss) to Owners Interests over Merger of the Face Company Value of GDRs ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Balance as on July 01, 2021 4,461,120,890 5,269,474,690 1,689,636,958 294,950,950 1,121,824,646 13,767,206 24,179,782,862 37,030,558,202 334,306,627 37,364,864,829 ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- NCI at the date of
acquisition-SPP - - - - - - - - 3,857,134,718 3,857,134,718 ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Total Comprehensive Income: Profit for the Year - - - - - - 5,123,136,712 5,123,136,712 (124,508,515) 4,998,628,197 ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Other Comprehensive Income/(Loss) - - - - - 6,764,517 - 6,764,517 - 6,764,517 ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Transactions with the Shareholders: Cash Dividend - - - - - - (1,561,392,312) (1,561,392,312) (31,426,189) (1,592,818,501) ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Adjustment for Depreciation on Revalued Assets - - - - (6,358,656) - 6,358,656 - - - ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Adjustment for Deferred Tax on Revalued Assets - - - - 1,430,698 - - 1,430,698 - 1,430,698 ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Balance as on June 30, 2022 4,461,120,890 5,269,474,690 1,689,636,958 294,950,950 1,116,896,688 20,531,723 27,747,885,918 40,600,497,817 4,035,506,641 44,636,004,458 ------------- ------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- --------------- Number of Shares 446,112,089 Net Asset Value (NAV) Per Share Tk. 91.01 ---------------------------------------------- ------------- ----------- ------------- ---------- --------------- --------------- ------------- ---------------
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows
For the Year ended June 30, 2023
Amount in Taka July 2022-June July 2021- 2023 June 2022 Cash Flows from Operating Activities: ---------------- ---------------- Receipts from Customers and Others 39,440,236,428 36,145,521,249 Payments to Suppliers and Employees (30,943,666,211) (28,584,815,294) ---------------- ---------------- Cash Generated from Operations 8,496,570,217 7,560,705,955 Interest Paid (1,272,368,534) (1,002,350,838) Interest Received 5,529,516 3,055,358 Income Tax Paid (1,144,944,341) (1,347,234,025) Net Cash Generated from Operating Activities 6,084,786,858 5,214,176,450 Cash Flows from Investing Activities: ---------------- ---------------- Acquisition of Property, Plant and Equipment (2,410,765,411) (2,815,211,828) Intangible Assets (299,262,244) (124,286,166) Investment in Subsidiary - (4,766,635,704) Disposal of Property, Plant and Equipment 23,353,504 24,063,832 Disposal of Intangible Assets 67,725,000 - Dividend Received 1,931,517 2,015,444 Net Cash Used in Investing Activities (2,617,017,634) (7,680,054,422) Cash Flows from Financing Activities: ---------------- ---------------- Net Increase /(Decrease) in Long Term Borrowings (1,763,267,386) 2,730,647,211 Net Increase/(Decrease) in Short Term Borrowings (229,380,048) 1,507,676,748 Dividend Paid (1,567,923,375) (1,623,098,759) ---------------- ---------------- Net Cash (Used in) / from Financing Activities (3,560,570,809) 2,615,225,200 Increase/(Decrease) in Cash and Cash Equivalents (92,801,585) 149,347,228 Cash and Cash Equivalents at Beginning of Year 1,168,673,821 973,963,625 Effect of Exchange Rate Changes on Cash and Cash Equivalents 59,813,942 45,362,968 ---------------- ---------------- Cash and Cash Equivalents at End of Year 1,135,686,178 1,168,673,821 Net Operating Cash Flows Per Share 13.64 11.69
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FR FLFSDIILLVIV
(END) Dow Jones Newswires
November 01, 2023 03:00 ET (07:00 GMT)
1 Year Beximco Pharma Chart |
1 Month Beximco Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions